Isosorbide Dinitrate (20mg), Hydralazine (37.5mg)..

Isosorbide Dinitrate (20mg), Hydralazine (37.5mg)
HYDROZOLIN ISDN

Introduction to Hydrozolin ISDN

Hydrozolin ISDN is a combination medication that consists of two primary active ingredients: Isosorbide Dinitrate (20 mg) and Hydralazine Hydrochloride (37.5 mg). This combination therapy is often used in managing heart conditions, particularly in patients with heart failure or chronic hypertension. The dual action of both drugs enhances cardiac efficiency and improves overall blood flow, making it especially valuable for patients with compromised cardiovascular systems.

Composition and Dosage of Hydrozolin ISDN

• Isosorbide Dinitrate (20 mg): Isosorbide Dinitrate is a nitrate that helps dilate blood vessels, reducing the strain on the heart. It works by releasing nitric oxide, which relaxes and widens blood vessels, improving oxygen delivery to the heart muscle.

• Hydralazine Hydrochloride (37.5 mg): Hydralazine is a vasodilator that works by relaxing the smooth muscles in blood vessel walls, primarily in the arteries. It lowers blood pressure and reduces the workload on the heart, aiding in better blood flow and reducing resistance.

Mechanism of Action of Each Component

The mechanism of action in Hydrozolin ISDN is rooted in the complementary effects of Isosorbide Dinitrate and Hydralazine:

• Isosorbide Dinitrate: It belongs to the nitrate class of drugs that release nitric oxide, a potent vasodilator, into the bloodstream. Nitric oxide directly causes relaxation of vascular smooth muscle, leading to dilated veins and arteries, which reduces preload (venous return to the heart) and afterload (resistance against which the heart pumps). By decreasing these pressures, Isosorbide Dinitrate decreases myocardial oxygen demand and alleviates symptoms of heart failure.

• Hydralazine: This drug specifically targets arterial smooth muscle, reducing the tone and resistance within arteries. It does not significantly affect venous smooth muscle, meaning its primary action is on the afterload rather than preload. By reducing afterload, Hydralazine allows the heart to pump more efficiently, as there is less resistance in the arterial system. Hydralazine’s mechanism complements that of Isosorbide Dinitrate, enhancing the overall efficacy of the drug combination.

Pharmacokinetics of Hydrozolin ISDN

The pharmacokinetics of Hydrozolin ISDN are defined by the individual properties of Isosorbide Dinitrate and Hydralazine:

• Isosorbide Dinitrate: After oral administration, Isosorbide Dinitrate is absorbed quickly, with peak plasma levels reached within an hour. It has a half-life of about 4-6 hours, though its effects on blood vessels can last longer due to the production of active metabolites.

• Hydralazine: Hydralazine also exhibits rapid absorption, reaching peak plasma levels in 1-2 hours post-administration. However, its bioavailability is variable because of the "first-pass effect" (metabolism in the liver), which can reduce the amount of the drug reaching systemic circulation. The drug has a half-life of approximately 3-7 hours, making it suitable for twice or thrice daily dosing depending on clinical needs.

Clinical Indications and Benefits

Hydrozolin ISDN is primarily indicated for:

• Heart Failure: Particularly in patients who do not respond well to other heart failure medications or in specific populations. The combination helps alleviate symptoms, improve exercise capacity, and reduce hospitalizations due to heart failure exacerbations.

• Hypertension: While it is not a first-line treatment for high blood pressure, Hydrozolin ISDN is beneficial in cases where patients do not respond adequately to other antihypertensive agents. The combination of Isosorbide Dinitrate and Hydralazine effectively reduces both preload and afterload, helping to control blood pressure.

• Race-Specific Indication: Studies have shown that this combination therapy is particularly effective in African American patients with heart failure, who may have different physiological responses to traditional heart failure therapies. The African American Heart Failure Trial (A-HeFT) demonstrated that patients with African heritage experienced significant survival benefits when using this combination, prompting the FDA to approve it as an adjunctive treatment for heart failure in this population.

Side Effects and Precautions

Like all medications, Hydrozolin ISDN has potential side effects. The most common side effects include:

• Headache: This is due to vasodilation caused by Isosorbide Dinitrate.
• Dizziness or Lightheadedness: Caused by the blood pressure-lowering effects of both medications.
• Gastrointestinal Issues: Including nausea and vomiting, mainly associated with Hydralazine.
• Reflex Tachycardia: The body may respond to the sudden drop in blood pressure by increasing heart rate.

Patients should be closely monitored for any adverse effects, particularly those with preexisting conditions. It's crucial to titrate the dose carefully and avoid abrupt withdrawal, as this can lead to rebound hypertension.

Drug Interactions

Hydrozolin ISDN can interact with other medications, so it’s important to review any other drugs a patient may be taking:

• Other Antihypertensives: Concurrent use may result in excessively low blood pressure, leading to symptomatic hypotension.
• Phosphodiesterase Inhibitors (e.g., Sildenafil): These drugs, often used for erectile dysfunction, can cause dangerously low blood pressure when used with nitrates.
• Monoamine Oxidase Inhibitors (MAOIs): When combined with Hydralazine, there is a risk of hypertensive crisis, as these medications can increase sympathetic activity.

Recommended Dosage and Administration

The typical dosage of Hydrozolin ISDN is based on individual needs but often starts with a standard dose taken three times daily.

In clinical practice, healthcare providers assess factors such as kidney function, liver health, and other cardiovascular medications the patient may be on to avoid adverse effects and optimize therapeutic outcomes.

Conclusion

Hydrozolin ISDN represents an effective combination therapy that leverages the benefits of Isosorbide Dinitrate and Hydralazine to support heart function and reduce blood pressure, particularly in heart failure patients. Its targeted action on preload and afterload makes it a versatile choice in cardiology, especially for patients who may not respond to other medications or who belong to certain demographics, such as African Americans, for whom this combination has proven to be particularly effective. Steris Healthcare Pvt Ltd, operating as Sterispharma since its founding by expert professionals in the pharmaceutical industry in February 2018, is based in Navi Mumbai. The company is certified by WHO, GMP, and ISO, emphasizing its commitment to quality and safety. Sterispharma focuses on providing high-quality drugs at affordable prices throughout India, adhering strictly to WHO guidelines. Offering the convenience of an online pharmacy, customers can easily purchase medicines with home delivery options available. Sterispharma's mission is to supply a broad range of healthcare products to meet the diverse needs of the medical community. From advanced treatments and medications for rare conditions to essential health necessities, Sterispharma aims to serve the extensive demands of the healthcare industry. You can order medicines from Sterispharma through their websites, Sterisonline  ,  Sterisindia and Sterispharma. Their extensive product lineup includes treatments for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. 

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 7877551268, 7849827488

BUY NOW